Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract
GI mastocytosis is highly predictive of SM in BM; however, most SM-BM+ patients are SM-GI-. The SM-BM- patients are very unlikely to be SM-GI+. Because GI neoplastic mast cells are often tryptase negative, diagnostic evaluation should include CD117 and CD25 immunohistochemistry, as well as KIT D816V mutation analysis by ddPCR as needed.
Authors
- Ayalew Tefferi
- Julie A. Majerus (ORCID: https://orcid.org/0000-0002-9960-4175)
- Animesh Dev Pardanani (ORCID: https://orcid.org/0000-0002-9084-4148)
- April Chiu (ORCID: https://orcid.org/0000-0002-6431-2666)
- Rong Lucy He (ORCID: https://orcid.org/0000-0001-6116-8163)
- Kaaren K. Reichard (ORCID: https://orcid.org/0000-0001-5439-0778)
- Dong Chen (ORCID: https://orcid.org/0000-0001-7627-9560)
- David S. Viswanatha
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1093/ajcp/aqaf112
- Primary Topic
- Mast cells and histamine
- Type
- article
- Field-Weighted Citation Impact
- 0.00